Cardiovascular Journal of Africa: Vol 30 No 1 (January/February 2019)

25 / 78

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 30, No 1, January/February 2019 AFRICA 23
Atherosclerosis Society of Southern Africa (LASSA). South African
dyslipidaemia guideline consensus statement. S Afr Med J 2012; 102:
178–187.
5. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR,
Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipi-
daemias. Eur Heart J 2011; 32: 1769–1818.
6. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et
al. National Lipid Association recommendations for patient-centered
management of dyslipidemia: part 1 – executive summary. J Clin Lipidol
2014; 8: 473–488.
7. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB,
Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood
cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report
of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889–2934.
8. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R,
et al. Alirocumab and cardiovascular outcomes after acute coronary
syndrome. N Engl J Med 2018; 379: 2097–2107.
9. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD,
Murphy SA, et al. Evolocumab and clinical outcomes in patients with
cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.
10. Hermans MP, Castro Cabezas M, Strandberg T, Ferrieres J, Feely J,
Elisaf M, et al. Centralized Pan-European survey on the under-treat-
ment of hypercholesterolaemia (CEPHEUS): overall findings from eight
countries. Curr Med Res Opin 2010; 26: 445–454.
11. Banegas JR, López-García E, Dallongeville J, Guallar E, Halcox JP,
Borghi C, et al. Achievement of treatment goals for primary preven-
tion of cardiovascular disease in clinical practice across Europe: the
EURIKA study. Eur Heart J 2011; 32: 2143–2153.
12. Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings
C, et al. EUROASPIRE IV: A European Society of Cardiology survey
on the lifestyle, risk factor and therapeutic management of coronary
patients from 24 European countries. Eur J Prev Cardiol 2016; 23:
636–648.
13. Raal F, Schamroth C, Blom D, Marx J, Rajput M, Haus M, et al.
CEPHEUS SA: a South African survey on the under-treatment of
hypercholesterolaemia. Cardiovasc J Afr 2011; 22: 234–240.
14. Raal FJ, Blom DJ, Naidoo S, Bramlage P, Brudi P. Prevalence of
dyslipidaemia in statin-treated patients in South Africa: results of the
DYSlipidaemia International Study (DYSIS). Cardiovasc J Afr 2013;
24: 330–338.
15. Danchin N, Almahmeed W, Al-Rasadi K, Azuri J, Berrah A, Cuneo
CA, et al. Achievement of low-density lipoprotein cholesterol goals in
18 countries outside of Western Europe: the International ChoLesterol
management Practice Study (ICLPS). Eur J Prev Cardiol 2018; 25(10):
1087–1094.
16. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer
G, et al. Estimation of ten-year risk of fatal cardiovascular disease in
Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
17. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA,
Theroux P, et al. Ezetimibe added to statin therapy after acute coronary
syndromes. N Engl J Med 2015; 372: 2387–2397.
18. World Health Organization Western Pacific Region, IASO international
Association for the Study of Obesity, International Obesity Taskforce.
The Asia-Pacific perspective: Redefining obesity and its treatment,
pdf (2000, accessed 25 June 2018).
19. Shisana O, Labadarios D, Rehle T, Simbayi L, Zuma K, Dhansay A, et
al. South African National Health and Nutrition Examination Survey
(SANHANES-1). Cape Town: HSRC Press
uploads/pageNews/72/SANHANES-launch%20edition%20(online%20
version).pdf (2013, accessed 25 June 2018).